<DOC>
	<DOCNO>NCT01895335</DOCNO>
	<brief_summary>Primary Objective : To describe efficacy , tolerability convenience teriflunomide treatment evaluation Participant Reported Outcomes ( PROs ) . Secondary Objectives : To describe disease progression use PROs . To describe clinical outcome ( ie , treated relapse ) teriflunomide treat participant . To describe change cognition teriflunomide treat participant . To describe safety teriflunomide participant treat ( base adverse event report ) . To describe adherence persistence teriflunomide treatment . To describe quality life , activity leisure period teriflunomide treatment . To compare Participant Determined Disease Steps ( PDDS ) Expanded Disability Status Scale ( EDSS ) assess Multiple Sclerosis ( MS ) disease progression .</brief_summary>
	<brief_title>Using Patient Reported Outcomes ( PROs ) Evaluate Teriflunomide Treatment Relapsing Multiple Sclerosis ( RMS ) Patients</brief_title>
	<detailed_description>The total duration study per participant 50 54 week ( accelerate elimination procedure perform ) : Screening : 2 week Teriflunomide treatment : 48 week Accelerated elimination procedure : 4 week perform An accelerated elimination procedure time discontinuation teriflunomide treatment possible particularly recommended woman child-bearing potential .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Inclusion criterion : Participants relapse form multiple sclerosis ( RMS ) sign write informed consent . Exclusion criterion : According local labelling , Less 18 year age , Current history receiving teriflunomide , Previous treatment leflunomide within 6 month prior baseline , Participants preexist acute chronic liver disease , serum alanine aminotransferase ( ALT ) great 2 time upper limit normal ( ULN ) , Known history active tuberculosis ( TB ) latent TB infection , either diagnosed standard medical practice guideline ( include skin blood test , chest Xray , appropriate per local practice ) , Known history severe immunodeficiency , acquire immunodeficiency syndrome ( AIDS ) , bone marrow disease , acute severe active infection , Women pregnant breastfeeding , Female participant positive pregnancy test screen woman childbearing potential agree use reliable contraception throughout course study , Male participant ( require accord local labeling ) : unwilling use reliable contraception course study , Additional exclusion criterion applicable Europe ( EU ) country ( accordance contraindication EU summary product characteristic [ SmPC ] ) : Participants significantly impair bone marrow function significant anaemia , leukopenia , neutropenia thrombocytopenia , Participants severe active infection resolution , Participants severe renal impairment undergoing dialysis , insufficient clinical experience available participant group , Participants severe hypoproteinaemia , e.g . nephrotic syndrome . Hypersensitivity active substance excipients , Other additional contraindication per local labeling . The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>